1. Kapur NK, Wilson S, Yunis AA, Qiao X, Mackey E, Paruchuri V, Baker C, Aronovitz MJ, Karumanchi SA, Letarte M, Kass DA, Mendelsohn ME, Karas RH. Reduced Endoglin Activity Limits Cardiac Fibrosis and Improves Survival in Heart Failure. Circulation. Accepted and in press 2012.
2. Kapur NK, Shenoy C, Yunis AA, Mohammad NN, Wilson S, Paruchuri V, Mackey EE, Qiao X, Shah A, Esposito M, Karas RH, Jaffe IZ. Distinct Effects of Unfractionated Heparin versus Bivalirudin on Circulating Angiogenic Peptides. PLoS One. Accepted and in press 2012.
3. Heffernan KS, Eshan A, Parvardhan A, Kapur NK, Karas RH, Kuvin JT. Peripheral augmentation index as a biomarker of vascular aging: an invasive hemodynamics approach. Eur J Appl Physiol. 2011 Dec 3. Epub ahead of print.
4. Kapur NK, Kociol R. Rise of the Machines... and their Mechanics. Catheter Cardiovasc Interv. 2011 Nov 15;78(6):962-3.
5. Korabathina R, Heffernan KS, Paruchuri V, Patel AR, Mudd JO, Prutkin JM, Orr N, Weintraub A, Kimmelstiel CD, Kapur NK. The Pulmonary Artery Pulsatility Index Identifies Severe Right Ventricular Dysfunction in Acute Inferior Myocardial Infarction. Catheter Cardiovasc Interv. 2011 Sep 27.
6. Heffernan KS, Kuvin JT, Patel A, Karas RH, Kapur NK. Endothelial function and Soluble Endoglin in Smokers with Heart Failure. Clin Card 2011 Nov 28.
7. Kapur NK, Paruchuri V, Korabathina R, Esposito M, Shah A, Sech C, Kiernan M, Patel A, Orr N, Pham DT, Konstam M, DeNofrio D. Effects of a Percutaneous Mechanical Circulatory Support Device for Medically Refractory Right Ventricular Failure. J Heart Lung Transplant. 2011 Dec; 30(12):1360-7.
8. Kapur NK, Bian Ce, Lin E, Sperry JL, Deming CB, Hansen BS, Rade JJ. Inhibition of Transforming Growth Factor-beta Restores Endothelial Thromboresistance in Vein Grafts. J Vasc Surgery. 2011 Jul 29 [Epub ahead of print]
9. Kapur NK. Transforming Growth Factor-beta: Governing the Transition from Inflammation to Fibrosis in Heart Failure with Preserved Left Ventricular Function. Circulation: Heart Failure 2011 Jan 1;4(1):5-7.
10. Kapur NK, Yunis AA, Parpos P, Heffernan KH, Aronovitz MJ, Baker C, Wilson S, Shah A, Epsoito M, Kimmelstiel CD, Weintraub A, Karas RH, Mendelsohn ME. Soluble fms-like Tyrosine Kinase (sFLT1): A Highly Sensitive Biomarker of Acute ST-segment Elevation Myocardial Infarction (STEMI). Arterioscler Thromb Vasc Biol. 2011 Feb;31(2):443-50.
View all of Dr. Kapur's publications on
PubMed.
Dr. Kapur is a dual, board-certified Interventional Cardiologist and Advanced Heart Failure/Cardiac Transplant specialist. He is Director of the Acute Circulatory Support Program and Associate Director of the Cardiac Catheterization Laboratory at Tufts Medical Center. His clinical expertise focuses on invasive hemodynamics, mechanical circulatory support, and interventional therapies for patients with advanced heart failure. He serves on several national committees involved with the American Heart Association, the American College of Cardiology, the Heart Failure Society of America, and the Society for Cardiac Angiography and Interventions.
As Director of the Interventional Research Laboratories at Tufts Medical , Dr. Kapur’s translational research focuses on large animal models of acute and chronic heart failure, circulatory support device development, and cardioprotective mechanisms in the setting of acute myocardial infarction. His recent work has focused on the hypothesis that mechanically unloading the heart and delaying coronary reperfusion limits infarct size. This concept known as the 'mechanical conditioning hypothesis' has the potential to alter the paradigm of acute heart attack therapy and reduce the burden of ischemic heart failure.
As Director of the Cardiac Biology Research Center within the Molecular Cardiology Research Institute at Tufts Medical Center, Dr. Kapur’s basic science laboratory focuses on molecular mechanisms governing maladaptive cardiac remodeling in heart failure. His particular expertise involves signaling via the transforming growth factor beta (TGFb) system. Over the past 6 years, the laboratory has published several critical papers focused on a TGFb co-receptor known as endoglin and was the first to establish that reduced endoglin activity improves survival and limits maladaptive cardiac remodeling in heart failure. More recently, the laboratory has demonstrated that targeting endoglin using an antibody-mediated approach not only limits the development of cardiac fibrosis, but can reverse established cardiac fibrosis in preclinical models of heart failure. Dr. Kapur is the recipient of grant funding from the National Institutes of Health, American Heart Association, and several industry sponsors.
Understanding the Translational Value of PV Loops from Mouse to Man
In this webinar, Dr. Kapur discusses how PV loop data can translate over from mouse to man and provide a confident approach to evaluating drug studies, device validation and treatments outcomes.
View on SlideShare >
